Incyte Corp.

How big is Incyte Corp.?

As of Jun 18, Incyte Corp. has a market capitalization of $13.32 billion, with net sales of $4.41 billion and a net profit of $21.27 million over the latest four quarters.

As of Jun 18, Incyte Corp. has a market capitalization of 13,319.55 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 4,413.23 million, while the sum of Net Profit for the same period is 21.27 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 3,447.63 million and Total Assets at 5,482.31 million.

What does Incyte Corp. do?

Incyte Corporation is a biopharmaceutical company specializing in the discovery and development of therapeutics. As of March 2025, it reported net sales of $1.053 billion and a market cap of approximately $13.32 billion.

Overview: <BR>Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,053 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 158 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 13,319.55 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 301.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.65 <BR>Return on Equity: 1.21% <BR>Price to Book: 3.63<BR><BR>Contact Details: <BR>Address: 1801 Augustine Cut off, WILMINGTON DE: 19803-4404 <BR>Tel: ['1 302 4986700', '1 302 4985914'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.incyte.com/

Should I buy, sell or hold Incyte Corp.?

Who are in the management team of Incyte Corp.?

As of March 2022, Incyte Corp.'s management team includes Herve Hoppenot as Chairman, President, and CEO, with Julian Baker as Lead Independent Director and independent directors Jean-Jacques Bienaime, Paul Clancy, Wendy Dixon, and Jacqualyn Fouse.

As of March 2022, the management team of Incyte Corp. includes Mr. Herve Hoppenot, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. Julian Baker holds the position of Lead Independent Director. The board also comprises independent directors: Mr. Jean-Jacques Bienaime, Mr. Paul Clancy, Dr. Wendy Dixon, and Dr. Jacqualyn Fouse.

Is Incyte Corp. technically bullish or bearish?

As of July 30, 2025, Incyte Corp. shows a bullish technical trend supported by strong MACD and moving averages, despite mixed signals from Dow Theory and OBV, while outperforming the S&P 500 year-to-date and over the past year, but underperforming over three- and five-year periods.

As of 30 July 2025, the technical trend for Incyte Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. Daily moving averages are bullish, while the KST shows bullish signals weekly and monthly. However, Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish monthly view. The On-Balance Volume (OBV) is mildly bearish weekly but bullish monthly.<BR><BR>In terms of performance, Incyte has outperformed the S&P 500 year-to-date with a return of 24.51% compared to 12.22%, and over the past year with 31.96% against 17.14%. However, over the longer three-year and five-year periods, it has significantly underperformed the benchmark.<BR><BR>Overall, the current technical stance is bullish, driven by strong MACD, Bollinger Bands, and moving averages, despite some mixed signals from Dow Theory and OBV.

Is Incyte Corp. overvalued or undervalued?

As of October 17, 2025, Incyte Corp. is considered overvalued with a P/E ratio of 301 and an EV to EBITDA ratio of 36.85, despite a short-term return of 31.82%, as its long-term performance has significantly lagged behind the S&P 500.

As of 17 October 2025, Incyte Corp. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 301, which is significantly higher than the peer average of approximately 22.95. Additionally, the EV to EBITDA ratio stands at 36.85, further indicating a premium valuation compared to industry norms.<BR><BR>In comparison to its peers, Incyte's Price to Book Value is 3.63, and its EV to Sales ratio is 2.47, both of which suggest that the stock is priced above its fundamental value. Notably, while Incyte has outperformed the S&P 500 in the short term with a 1-year return of 31.82% versus 14.08%, its long-term performance has lagged, with a 5-year return of -3.38% compared to the S&P's 91.29%. This discrepancy reinforces the notion that the stock may be overvalued relative to its growth prospects.